KRAS protein is a key driver of most cases of pancreatic cancer. KRAS, working via leukemia inhibitory factor, promotes the generation and maintenance of pancreatic cancer stem cells. LIF shows promise as a target for pancreatic cancer treatment. LAKE TAHOE, Nev. — Pancreatic cancer is one of the...
Posted to
News
by
AACR News
on
Tue, Jun 19 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, stem cells, pancreatic cancer, KRAS, Pancreatic Cancer: Progress and Challenges, leukemia inhibitory factor, Dr. Man-Tzu Wang, LIF
Novel Hsp90 inhibitor shows activity in slowing KRAS-mutant NSCLC tumor cell growth. Use with traditional chemotherapy resulted in increased cancer cell death. Phase 2b/3 trial combined with docetaxel under way. SAN DIEGO — The investigational drug ganetespib, a synthetic second-generation Hsp90...
Posted to
News
by
AACR News
on
Tue, Jan 10 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, genetics, KRAS, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, NSCLC, Jaime Acquaviva, David A. Proia, ganetespib, clinical trials, Hsp90 inhibitor
Survival rates were “unsatisfactory” in patients with NSCLC and a KRAS mutation. “Great need” exists for new treatment combinations in this patient population. SAN DIEGO — Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but...
Posted to
News
by
AACR News
on
Mon, Jan 9 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, sorafenib, KRAS, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, NSCLC, Wouter W. Mellema
Aggressive lung cancers harboring KRAS mutations are sensitive to antifolates. Antifolates decrease KRAS gene expression. Large clinical trials needed to investigate antifolate effects in cancers with respect to driving mutations. SAN FRANCISCO — Patients with non-small cell lung cancer who have...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, mutations, meeting, National Cancer Institute, NCI, KRAS, non-small cell lung cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, pemetrexed, antifolates, methotrexate, Dr. Sarah Bacus